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indicated several problems with that document. Some of those
problems have been solved in this new classification (e.g., the
inclusion of fatal cases of MI). This new classification includes
spontaneous MI (type 1), MI secondary to ischemia due to either
increased oxygen demand or reduced supply (type 2), sudden
cardiac deaths or cardiac arrest (type 3), MI associated with
percutaneous coronary intervention (type 4), and MI associated
with coronary artery bypass grafting (type 5). This classification
could be useful to develop future studies analyzing different
treatments according to the group to which the patient belongs.
However, it is our opinion that an important group of patients has
been forgotten: those with MI related to noncardiac surgeries. The
etiology and pathophysiology of myocardial ischemia and infarc-
tion in this setting are still controversial subjects and could fit
either in types 1 or 2. Based on pathology studies (3,4), we believe
that perioperative MI have similar pathophysiology to spontaneous
MI; therefore, they should be treated the same way. As a
complement of Thygesen’s classification, we suggest the inclusion
of MI after noncardiac surgeries in type 1 MI of the new
classification because this inclusion may have implications for the
management of acute coronary syndromes in this setting.
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Reply
We thank Dr. Gualandro and colleagues for their thoughtful
letter. We have considered a number of different clinical scenarios
but decided not to target every specific clinical situation, because
there are too many to be contained within the framework of the
European Society of Cardiology/American College of Cardiology
Foundation/American Heart Association/World Heart Federation
expert consensus document (1).
We agree that there is a great deal to learn about perioperative
myocardial infarctions as the pathophysiology of these differs
somewhat from that of myocardial infarction occurring in the usual
setting. We also agree that it can be hard to tell whether these
infarctions are type 1 or type 2. However, there are some data to
guide us.
Studies of patients undergoing noncardiac surgery strongly
support the concept that many of the infarctions diagnosed in this
connection are caused by prolonged imbalance between myocardial
oxygen supply and demand on the background of coronary artery
disease (2,3), which together with rise and fall of cardiac markers
points toward myocardial infarction type 2.
The fact that many such patients have type 2 infarctions should
not obscure the likelihood that some of the infarctions are type 1
as well. Pathology of fatal peri- or post-operative myocardial
infarctions shows plaque rupture and platelet aggregation leading
to thrombus formation in approximately half of these events (4).
Given the differences that likely exist in the therapeutic approaches
to each, close clinical scrutiny to identify this group is essential.
Some patients may not have myocardial infarction at all. Careful
clinical evaluation including a detailed history, examination, and
evaluation of further investigations to identify and treat those with
pulmonary embolism, sepsis, and/or the many other conditions
associated with myocyte necrosis and troponin elevations is
strongly advocated (1).
Although we cannot make criteria for all clinical judgments
such as this one, the available information suggests that the use of
contemporary troponin assays (5,6) and the decision levels advo-
cated by the expert consensus document (1) maximizes the ability
to identify patients with this diagnosis and then to configure the
care according to the type based on that judgment.
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Pre-Transplant
Toxoplasma gondii
Seropositivity Among Heart
Transplant Recipients and Mortality
Arora et al. (1) recently reported that pre-transplant Toxoplasma
gondii (T. gondii) seropositivity was associated with increased risks
of advanced cardiac allograft vasculopathy, mortality attributable to
cardiac allograft vasculopathy, and all-cause mortality. These
investigators are to be congratulated on recognizing the possible
relevance of chronic T. gondii infection, a hitherto underinvesti-
gated aspect of the response to heart transplant (HT). If their
conclusions are corroborated, they may have significant implica-
tions for HT patient management, especially in centers such as
ours, where the prevalence of T. gondii seropositivity among HT
patients (75%) is much higher than the 27% reported by Arora
et al. (1).
It is nevertheless disappointing that the investigators did not
provide more information on the analyses that led them to their
conclusions. They state that they used stepwise Cox regression
analyses including all variables with p values 0.05 in the
univariate analyses, but candidate variables not included in the Cox
analysis are not named and the strengths of the univariate
associations are not given.
Furthermore, in adopting this combination of a purely statistical
criterion for variable inclusion in the regression model, in opposi-
tion to a clinically oriented analysis, variables of established clinical
relevance have been left apart. Although factors such as pre-
transplantation coronary artery disease, ischemia time, donor age,
recipient age, diabetes, cytomegalovirus infection, or previous
rejection episodes may not have differed significantly between the
T. gondii seropositive and seronegative groups in this study, they
affect HT outcome (2) and should have been taken into account
regardless of their statistical significance. Minor differences work-
ing in the same direction could explain a substantial part of the
reported relationship, and their exclusion calls into question the
accuracy of the association between T. gondii seropositivity and
end points.
The failure to tell the reader which variables were tested by
univariate analysis severely limits the ability of other researchers to
compare the findings of Arora et al. (1) with their own results, and
infringes the principle that the description of research methods
should suffice to allow replication by others. We would really
appreciate if the investigators could provide detailed information
about statistical methods in associated online repositories.
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Reply
We agree with the suggestion by Dr. Flores-Rı´os and colleagues
that our findings may have significant implications for the man-
agement of heart transplant recipients, particularly in geographical
regions where Toxoplasma gondii seropositivity is virtually endemic.
Although our article (1) has shown an independent association
between seropositivity and long-term outcome, our de novo findings
do need to be corroborated by other centers.
Flores-Rı´os et al. write that our article does not list candidate
variables that were not included in the Cox analysis. We agree that
some of the methods could have been more thoroughly described,
but this omission was at least partly attributable to space limitation.
Nevertheless, we refer to the Statistical Analysis section of our
article and would like to emphasize that all variables listed in Table
1 were candidate variables for the Cox analysis. All of these
variables were initially tested using the Kaplan-Meier method, and
if this found a significant association (p 0.05) with the end point
(mortality or allograft vasculopathy), the variable was included in
the multivariate Cox analysis.
We collected data on a large number of covariates (n 26), and
to avoid overzealous modeling, it is important to identify unim-
portant covariates. Simulation work has shown that at least 10
events need to be observed for each covariate included in multi-
variate modeling to allow an accurate analysis (2). Given such
statistical constraints, it is common to use a p value 0.05 on
univariate analysis to guide selection of covariates for multivariate
analysis (3,4). We do not dispute the suggestion that the inclusion
of known prognostic factors is relevant, but this should not be done
at the expense of overmodeling or exclusion of statistically signif-
icant variables. Dr. Flores-Rı´os and colleagues claim that factors
such as ischemia time, rejection episodes, and cytomegalovirus
infection should be taken into account regardless of statistical
significance. However, we believe that it is not appropriate to
include nonsignificant parameters in multivariate analyses, partic-
ularly in relatively small study populations. Furthermore, not all of
the suggested variables by Dr. Flores-Rı´os and colleagues are
established to be equally relevant. For example, in the recent study
be Hussain et al. (5), cytomegalovirus infection was not found to
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